Wosulin 30/70 40IU/ml Injection is a premixed insulin formulation containing 70% insulin isophane (NPH insulin) and 30% human insulin, designed for the management of diabetes mellitus requiring insulin therapy. The combination provides both intermediate-acting and short-acting insulin, facilitating effective glycemic control by addressing both basal and prandial insulin requirements. Insulin isophane acts as an intermediate-acting insulin, offering prolonged glucose-lowering effects, while human insulin provides rapid onset to manage postprandial glucose excursions. Wosulin 30/70 is indicated for patients with type 1 and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone do not achieve adequate glycemic control. The injection should be administered subcutaneously, with dosage individualized based on patient needs, blood glucose monitoring, and clinical response. It is essential to rotate injection sites to reduce the risk of lipodystrophy. Caution is advised to avoid hypoglycemia, and patients should be educated on recognizing and managing low blood sugar episodes. Wosulin 30/70 is contraindicated in patients with hypersensitivity to insulin or its excipients and should be used with caution in conditions affecting insulin absorption or metabolism. Regular monitoring of blood glucose and adjustment of therapy are crucial for optimal diabetes management.